Any current/future new fundraising through debt or equity?

The transcript from the earnings call on page 22 and surrounding pages does not mention any current or planned fundraising through debt or equity. As of September 30, 2023, the company holds a gross debt of Rs. 109 crores but maintains a net debt-free status with Rs. 236 crores in cash and cash equivalents. No specific references were made to raising additional funds via debt or equity in the near future. The management focuses on organic growth through existing projects and new tenders without highlighting fundraising plans. Any significant capital expenditures, such as on Rajasthan, are curr

Any current/future capex/capital investment/strategic investment?

The company is investing in setting up new laboratories and collection centers as part of various Public-Private Partnership (PPP) projects across states like Assam, Odisha, Maharashtra (CT project), Himachal Pradesh, and Mumbai (BMC project). They have invested in expanding the Mumbai lab to support the rapid operationalization of around 462 centers under the BMC contract. Ongoing capex includes setting up Radiology centers, Pathology labs, and collection centers which require upfront costs for equipment, manpower, interiors, infrastructure, and logistics. While initial quarters incur higher

Future growth expectations in sales/revenue/volumes?

The company targets a sustained revenue growth of approximately 30% CAGR for FY24 and FY25, excluding the Rajasthan project. FY24 expects around Rs. 600 crores revenue with Rs. 180-200 crores per quarter in FY25. New projects in Odisha, Assam, Maharashtra CT, Himachal Pradesh, and BMC are key growth contributors for FY25. Rajasthan project revenue potential has revised upward to Rs. 300 crores due to district reorganization, though commercialization may shift to FY25. Additional tenders, including a large radiology tender in Andhra Pradesh and others in the pipeline, are expected to add Rs. 14

Current/ Expected Orderbook/ Pending Orders?

Rajasthan contract: Revenue potential revised from Rs. 150 crores to Rs. 300 crores due to reorganization of districts from 33 to 50; contract terms remain unchanged. Pending execution of agreements expected soon after High Court order; commercial revenues anticipated from next fiscal. Other major active PPP projects in pipeline: Odisha, Assam, Maharashtra CT project, Himachal Pradesh, BMC project. New tenders: Andhra Pradesh (Radiology), other states in evaluation but details not disclosed yet. Expected additional topline from new tenders excluding Rajasthan: ~Rs. 140 crores in FY25, with max

Krsnaa Diagnost.Q2 FY24Healthcare Services

Krsnaa Diagnost. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹555P/E: 18.0Market Cap: ₹1.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company targets a sustained revenue growth of approximately 30% CAGR for FY24 and FY25, excluding the Rajasthan project.
FY24 expects around Rs. 600 crores revenue with Rs. 180-200 crores per quarter in FY25.
New projects in Odisha, Assam, Maharashtra CT, Himachal Pradesh, and BMC are key growth contributors for FY25.
Rajasthan project revenue potential has revised upward to Rs. 300 crores due to district reorganization, though commercialization may shift to FY25.
Additional tenders, including a large radiology tender in Andhra Pradesh and others in the pipeline, are expected to add Rs. 140 to Rs. 200 crores top-line by FY25 and beyond.
Mature centers and existing projects also expected to grow at 8-30%, supporting overall 30% growth trajectory.
B2C business segment gradually scaling up with positive early traction.

Margin guidance

Category 3

- Krsnaa Diagnostics expects to maintain a 30% year-on-year revenue growth trajectory for FY25, supported by ramping up projects in Odisha, Assam, Maharashtra (CT project), BMC (Mumbai), Himachal Pradesh, and Punjab. - EBITDA margins are projected to improve, targeting a sustainable range of 26-28% for FY24, with further margin expansion anticipated in FY25 as more projects mature and operational efficiencies improve. - The company expects reported EBITDA margins of around 25% for FY24, including the impact of ongoing implementation costs, which will reduce as projects mature. - Net profit margins grew to 7% in Q2 FY24 and 12% normalized in H1 FY24; projections indicate continued growth in profitability with operational scale and cost control. - The ramp-up of new labs and centers, including expected contributions from Assam and Odisha starting Q4 FY24, are key to margin and profit growth. - B2C segment growth and expansion into wellness packages add incremental revenue streams. Overall, Krsnaa Diagnostics anticipates robust future earnings growth driven by strategic project implementations and operational efficiencies.

See what Krsnaa Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript from the earnings call on page 22 and surrounding pages does not mention any current or planned fundraising through debt or equity.
As of September 30, 2023, the company holds a gross debt of Rs. 109 crores but maintains a net debt-free status with Rs. 236 crores in cash and cash equivalents.
No specific references were made to raising additional funds via debt or equity in the near future.
The management focuses on organic growth through existing projects and new tenders without highlighting fundraising plans.
Any significant capital expenditures, such as on Rajasthan, are currently minimal and expensed rather than capitalized.
For inquiries, investors are encouraged to contact the Investor Relations Team, but no fundraising announcements were disclosed in this call.

Order book

Yes

Rajasthan contract: Revenue potential revised from Rs. 150 crores to Rs. 300 crores due to reorganization of districts from 33 to 50; contract terms remain unchanged. Pending execution of agreements expected soon after High Court order; commercial revenues anticipated from next fiscal.
Other major active PPP projects in pipeline: Odisha, Assam, Maharashtra CT project, Himachal Pradesh, BMC project.
New tenders: Andhra Pradesh (Radiology), other states in evaluation but details not disclosed yet.
Expected additional topline from new tenders excluding Rajasthan: ~Rs. 140 crores in FY25, with maximum potential up to Rs. 200 crores.
Existing projects and new tenders combined aimed to sustain around 30% year-on-year growth in revenues.
Punjab tender fully implemented; revenue ramping up with new home collection services.
Order execution timelines: Maharashtra CT project expected completed by FY24-end; Rajasthan possibly delayed to next fiscal due to elections.

See what Krsnaa Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is investing in setting up new laboratories and collection centers as part of various Public-Private Partnership (PPP) projects across states like Assam, Odisha, Maharashtra (CT project), Himachal Pradesh, and Mumbai (BMC project).
They have invested in expanding the Mumbai lab to support the rapid operationalization of around 462 centers under the BMC contract.
Ongoing capex includes setting up Radiology centers, Pathology labs, and collection centers which require upfront costs for equipment, manpower, interiors, infrastructure, and logistics.
While initial quarters incur higher expenses due to front-loaded investments, these centers typically mature after 2-3 years, leading to improved margins.
No significant capitalization has been made for the Rajasthan project yet; only operational expenses have been incurred and expensed out.
They expect capex costs to reduce over time as projects mature and ramp up operations, contributing positively to margins going forward.

Track Krsnaa Diagnost. — get its next earnings analysis in your feed

How does Krsnaa Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisKrsnaa Diagnost.

Rev 2Mar 3

See where Krsnaa Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Krsnaa Diagnost. rank in Healthcare Services?

Compare Krsnaa Diagnost. against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →